Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shot up 5% during mid-day trading on Tuesday . The company traded as high as $12.36 and last traded at $11.06. 42,958,879 shares changed hands during mid-day trading, an increase of 85% from the average session volume of 23,231,602 shares. The stock had previously closed at $10.53.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on RXRX. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th.
Get Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Stock Down 10.3 %
The business has a fifty day moving average price of $7.52 and a two-hundred day moving average price of $7.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of -6.07 and a beta of 0.86.
Institutional Trading of Recursion Pharmaceuticals
A number of hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $54,000. CSS LLC IL purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $366,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Recursion Pharmaceuticals by 5.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company's stock worth $15,272,000 after buying an additional 118,428 shares during the last quarter. Vident Advisory LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $80,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $544,000. Hedge funds and other institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
